TITLE

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel

AUTHOR(S)

Geisler, Tobias; Booth, Jean; Tavlaki, Elli; Karathanos, Athanasios; Müller, Karin; Droppa, Michal; Gawaz, Meinrad; Yanez-Lopez, Monica; Davidson, Simon J.; Stables, Rod H.; Banya, Winston; Zaman, Azfar; Flather, Marcus; Dalby, Miles

PUB. DATE

August 2015

SOURCE

PLoS ONE;8/28/2015, Vol. 10 Issue 8, p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders, is limited. Objectives: To determine the effects of prasugrel loading on platelet function in patients on clopidogrel and high platelet reactivity undergoing percutaneous coronary intervention for acute coronary syndrome (ACS). Patients: Patients with ACS on clopidogrel who were scheduled for PCI found to have a platelet reactivity ≥40 AUC with the Multiplate Analyzer, i.e. “poor responders” were randomised to prasugrel (60 mg loading and 10 mg maintenance dose) or clopidogrel (600 mg reloading and 150 mg maintenance dose). The primary outcome measure was proportion of patients with platelet reactivity <40 AUC 4 hours after loading with study medication, and also at one hour (secondary outcome). 44 patients were enrolled and the study was terminated early as clopidogrel use decreased sharply due to introduction of newer P2Y12 inhibitors. Results: At 4 hours after study medication 100% of patients treated with prasugrel compared to 91% of those treated with clopidogrel had platelet reactivity <40 AUC (p = 0.49), while at 1 hour the proportions were 95% and 64% respectively (p = 0.02). Mean platelet reactivity at 4 and 1 hours after study medication in prasugrel and clopidogrel groups respectively were 12 versus 22 (p = 0.005) and 19 versus 34 (p = 0.01) respectively. Conclusions: Routine platelet function testing identifies patients with high residual platelet reactivity (“poor responders”) on clopidogrel. A strategy of prasugrel rather than clopidogrel reloading results in earlier and more sustained suppression of platelet reactivity. Future trials need to identify if this translates into clinical benefit. Trial Registration: ClinicalTrials.gov

ACCESSION #

109165250

 

Related Articles

• PROMETHEUS. Nierengarten, Mary Beth; Baber, Usman // MD Conference Express;May2015, Vol. 15 Issue 10, p4 

  The retrospective PROMETHEUS study demonstrated that patients with an acute coronary syndrome who underwent percutaneous coronary intervention were more likely to be treated by their physicians with prasugrel as opposed to clopidogrel if they were younger and had a lower risk factor burden. The...

• Contrast Induced Nephropathy in Patients with Acute Coronary Syndrome. Ugur, Mehmet Can; Ekinci, Ferhat; Soyaltın, Utku Erdem; Akar, Harun // BANTAO Journal;2015, Vol. 13 Issue 1, p10 

  Introduction. Contrast-induced nephropathy (CIN) is associated with increased morbidity and mortality after percutaneous coronary intervention (PCI). On the other hand, CIN is a serious complication in patients with diabetes or renal impairment undergoing percutaneous coronary intervention...

• Double stent loss during multivessel percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome. Hawranek, Michał; Desperak, Piotr D.; Gąsior, Paweł M.; Piegza, Jacek; Cislak, Aneta; Lekston, Andrzej; Gasior, Mariusz // Advances in Interventional Cardiology;2014, Vol. 10 Issue 2, p114 

  The following description presents a case of a 75-year-old female patient with non-ST-segment elevation acute coronary syndrome in whom there occurred an infrequent complication of percutaneous coronary angioplasty: uncontrolled intracoronary stent displacement from a balloon catheter. During...

• Same Day Discharge after PCI can also be Safe in High Risk Patients and Acute Coronary Syndrome. Hodkinson, Emily C.; Hanratty, Colm G.; Spence, Mark S.; Walsh, Simon J. // Heart, Lung & Circulation;Dec2015, Vol. 24 Issue 12, p1233 

  No abstract available.

• Effect of HemoglobinA1C on the coronary flow velocity after percutaneous coronary intervention. Zheng-Bin Wang; Chung-Guang Qiu; Shou-Jun Wang; Zhan-Ying Han; Zhen-Wen Huang; Guo-ju Sun // Biomedical Research (0970-938X);2015, Vol. 26 Issue 4, p677 

  The aims of this study was to explore the effects of hemoglobinAlC (HbAlc) levels on the flow velocity through arteries of patients treated with percutaneous coronary intervention (PCI) for acute coronary syndrome. A total of 220 acute coronary syndrome patients treated with PCI were selected...

• The Study of Factors Associated with Severity of In-Stent Restenosis in Patients Treated with PCI for Acute Coronary Syndromes. Blendea, Ciprian; Chitu, Monica; Orzan, Marius; Bajka, Balázs; Craciun, Adriana; Benedek, Imre // Acta Medica Marisiensis;Mar2016, Vol. 62 Issue 1, p64 

  Introduction: The management of in stent restenosis represents a topic of great actuality and interest, especially since the interventional treatment with stent implantation became largely accepted as the metod of choice in patients with acute coronary syndromes. Identification of certain risk...

• Multivessel versus Single Vessel Angioplasty in Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Metaanalysis. Mariani, Javier; Macchia, Alejandro; De Abreu, Maximiliano; Gonzalez Villa Monte, Gabriel; Tajer, Carlos // PLoS ONE;2/17/2016, Vol. 11 Issue 2, p1 

  Background: Multivessel disease is common in acute coronary syndrome patients. However, if multivessel percutaneous coronary intervention is superior to culprit-vessel angioplasty has not been systematically addressed. Methods: A metaanalysis was conducted including studies that compared...

• Pre- and in-hospital antithrombotic management patterns and in-hospital outcomes in patients with acute coronary syndrome: data from the Turkish arm of the EPICOR study. Ertaş, Fatih Sinan; Tokgözoğlu, Lale // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Dec2016, Vol. 16 Issue 12, p900 

  Objective: To evaluate the acute phase (pre- and in-hospital) antithrombotic management patterns (AMPs) and in-hospital outcomes for patients hospitalized with an acute coronary syndrome (ACS). Methods: In total, 1034 patients [514 patients with ST-segment elevation myocardial infarction (STEMI)...

• Clinical efficacies of percutaneous coronary intervention in patients with maintaining hemodialysis combined with acute coronary syndrome. Hua Wu; Panpan Liu; Chen Chen; Bihu Gao // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 11, p22398 

  Objective: The aim of this study was to investigate the safety and efficacy of percutaneous coronary intervention (PCI) in patients maintaining hemodialysis complicated with acute coronary syndrome (ACS). Methods: 15 patients maintaining hemodialysis complicated with ACS were selected. PCI were...

Read the Article